Skip to content

CEO Spotlight: James West

CEO Spotlight: James West

As a former academic coordinator for the City University of New York Research Foundation and Medgar Evers College, CEO and co-founder of Arfinn Med, James West, has extensive experience in adult education and professional training programming. James put this extensive education to good use when he noticed that there was a direct need for a new Electronic Medical Record system in the medical marijuana industry.

James first became interested in CBD and its benefits after coming across a number of news stories covering the revolutionary medical treatment. To start his journey into the medical marijuana industry, James conducted research on his own and spoke with numerous medical professionals on the topic. While researching, he realized that many medical professionals were interested in prescribing medical cannabis, but lacked access to sufficient research and data.

To help fix this issue, James created Arfinn Med, the first ever clinician-based medical professional and patient efficacy portal for medical marijuana treatment. With his experience top-of-mind, James’ objective for creating the Arfinn Med portal was to provide a digital warehouse of data from credible medical sources.

Arfinn Med is a free service that welcomes any and all licensed medical professionals to register, no matter the state of practice and medical marijuana legalization. Some additional features the portal provides Arfinn Med members include direct patient updates, the ability to view previous case studies conducted by licensed medical professionals, industry updates and so much more!

If you’re ready to join a nationwide network of licensed medical professionals to learn and share best practices and treatment efficacies for medical marijuana, join Arfinn Med for free today.

Stories you may be interested in

Cannabis and autism, explained

Over the past decade, autistic people and their families have increasingly experimented with medical marijuana and products derived from it. Many hope these compounds will alleviate a range of autism-related traits and problems. But scientists are still in the early stages of rigorous research into marijuana’s safety and effectiveness, which means that people who pursue…
Read More

New Feature: Calendar Integration

At Arfinn Med, we’re excited to announce the third feature update to join automated text messaging and note templating: calendar integration. With this addition, physicians can now integrate their Google Calendar or Calendy account. The implementation of calendar integration rounds out the Arfinn Med portal, making it a physician’s one-stop-shop EMR tool. How It Works…
Read More

More Treatment Options, Better Patient Outcomes

As more states start to pass medical marijuana legislation, patients benefit from having more options available to them regarding their treatment.  In fact, a recent study from Columbia University’s Irving Medical Center found that, “States with active medical marijuana laws saw certain opioid prescription rates drop nearly 20 percent compared to states without medical marijuana…
Read More

Former Detroit Lions players announce partnership with Harvard to study marijuana

Former Detroit Lions football players Calvin Johnson and Robert Sims are expanding their emerging cannabis enterprise into the field of medicine. The pair announced an agreement Thursday with the International Phytomedicines and Medical Cannabis Institute at Harvard University, which is researching the benefits of medical marijuana and looking at the best ways to deliver cannabis-based…
Read More

Military Times: “Our veterans deserve the well-being that medical cannabis can provide.”

The physical and mental trauma that veterans experience as a result of their military service extends far beyond the end of their participation in combat-related roles. To recognize the sacrifices veterans have made to protect our country, state and federal lawmakers must continue to expand access to crucial treatment options and programs that assist veterans…
Read More

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city. MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and…
Read More